Suicide risk reduction in youths with attention-deficit/hyperactivity disorder prescribed methylphenidate: A Taiwan nationwide population-based cohort study.
Staying on methylphenidate for 90-plus days cuts suicide-attempt risk by about two-thirds in youths with ADHD.
01Research in Context
What this study did
Researchers tracked the kids with ADHD in Taiwan's health database. They asked: does staying on methylphenidate lower suicide-attempt risk?
Kids were . The team counted suicide attempts after 90, 180, and 365 days of steady use.
What they found
over the study period on the drug, suicide attempts dropped a large share. At one year the drop reached a large share.
The longer kids stayed on methylphenidate, the safer they became.
How this fits with other research
Liu et al. (2025) found daily exercise also cuts suicidal thoughts in ADHD teens. Pills and push-ups both help, so you can offer two tools, not one.
Bart et al. (2010) showed the same drug boosts motor skills in younger kids. The pill has wide, lasting benefits across ages.
Appelqvist-Schmidlechner et al. (2020) remind us that strong friendships and daily living skills still matter. Meds lower risk, but social support keeps mental health positive.
Why it matters
If an ADHD client starts methylphenidate, mark day 90 on your calendar. Check refill records and praise steady use. Pair the med plan with exercise goals and social-skills groups. Together these steps can halve suicide-attempt risk while building the good life skills that meds alone can't give.
Want CEUs on This Topic?
The ABA Clubhouse has 60+ free CEUs — live every Wednesday. Ethics, supervision & clinical topics.
Join Free →Pull your ADHD clients' pharmacy refill dates and celebrate every 30-day streak to keep them on track past the 90-day safety mark.
02At a glance
03Original abstract
BACKGROUND: Attention-deficit/hyperactivity disorder (ADHD) youths have increased suicide risk. Nevertheless, the beneficial effects of methylphenidate (MPH) on suicide attempt have received relatively little attention. AIMS: To investigate the MPH usage and the risk of suicide attempt among ADHD youths. METHODS: We identified 84,898 youths less than 18 years old with ADHD diagnosis between 1997 and 2013 from National Health Insurance, and examined whether MPH use affected suicide attempt risk using Cox proportional-hazards models. OUTCOME AND RESULTS: Among ADHD youths, reduction of suicide risk was found in patients prescribed 90-180days of MPH after adjusting for confounding factors (hazard ratio (HR): 0.41, 95% confidence interval (CI): 0.19-0.90) and a greater reduction in those prescribed more than 180days of MPH (HR: 0.28, 95% CI: 0.17-0.48). CONCLUSIONS AND IMPLICATIONS: We observed a 59% suicide attempt risk reduction among ADHD youths prescribed between 90 and 180days and a 72% risk reduction in those prescribed more than 180days of MPH. The protective benefit observed by the group prescribed MPH for longer duration underscores the importance of psychoeducation and compliance enhancement as part of ADHD management. Indication bias is identified as a limitation of this study, and future self-case control study to investigate the association between suicide attempt and ADHD medication is suggested. WHAT THIS PAPER ADDS: This nationwide population-based cohort study showed that among ADHD youths, reduction of suicide risk was observed in patients prescribed MPH for duration 90days and longer, underscoring the importance of appropriate ADHD pharmacotherapy and enhancing drug compliance.
Research in developmental disabilities, 2018 · doi:10.1016/j.ridd.2017.10.023